FGF/FGFR1,2 targeting can attenuate lung parenchymal and vascular remodeling: an opportunity for drug repurposing against chronic lung disease and post COVID‐19 sequelae. - Kulshrestha, R.; Rani, M.; Dahiya, R.; Singh, A.; Doraiswamy, S.; Bharadwaj, S.; Batra, J.; Kumar, P.; Pandey, A.; Dinda, A. K.; Krishnan, R.; Mishra, A. K. (Surgical & Experimental Pathology, 2025)